Rocket Pharmaceuticals, Inc. Asset Impairment Charges
Rocket Pharmaceuticals, Inc. (RCKT) reported Asset Impairment Charges of $437.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. asset impairment charges for the quarter ending 2017-12-31 was $14.00K.
- Rocket Pharmaceuticals, Inc. asset impairment charges for fiscal 2017 was $437.00K.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|
| 2017-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $437.00K 10-K · filed 2018-03-07 | |
| 2017-09-30 | $423.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |